Zelira Therapeutics (ASX:ZLD) Total Operating Expense: A$3.80 Mil (TTM As of Jun. 2025)


What is Zelira Therapeutics Total Operating Expense?

Zelira Therapeutics ASX:ZLD Total Operating Expense is A$3.80 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Zelira Therapeutics's Total Operating Expense for the six months ended in Jun. 2025 was A$2.17 Mil. Zelira Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 was A$3.80 Mil.

Zelira Therapeutics Total Operating Expense Related Terms

Zelira Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Total Operating Expense Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.20 14.25 7.20 5.95 3.80

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.87 3.30 2.65 1.64 2.17

Zelira Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of A$3.80 Mil mean?
Zelira Therapeutics (ASX:ZLD) has a Total Operating Expense of A$3.80 Mil as of Jun. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Total Operating Expense too high?
Zelira Therapeutics' current Total Operating Expense is A$3.80 Mil.
How does Zelira Therapeutics' Total Operating Expense compare to MTNB and SXTP?
Zelira Therapeutics' Total Operating Expense of A$3.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Total Operating Expense is A$3.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Total Operating Expense of A$3.80 Mil. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Total Operating Expense is A$3.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Total Operating Expense is A$3.80 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.